Lexeo Therapeutics, Inc.
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
LXEO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US52886X1072
- LEI:
- Country:
- United States of America
- Address:
- 345 PARK AVENUE SOUTH, 10010 NEW YORK
- Website:
- https://www.lexeotx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing curative treatments for genetically defined diseases. The company advances a pipeline of investigational AAV-mediated gene therapies, with a primary focus on genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. Building on foundational research from Weill Cornell Medicine and the University of California San Diego, Lexeo's strategy prioritizes efficient development, advanced manufacturing, and strategic partnerships with leading research institutions to develop high-impact therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lexeo Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lexeo Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lexeo Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
